4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Raised to $35.00 at Royal Bank Of Canada

4D Molecular Therapeutics (NASDAQ:FDMT) had its price target upped by Royal Bank Of Canada from $32.00 to $35.00 in a research note published on Thursday morning,Benzinga reports. They currently have an outperform rating on the stock.

Several other research firms have also recently weighed in on FDMT. Barclays began coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price objective for the company. Chardan Capital reissued a “buy” rating and set a $26.00 price target on shares of 4D Molecular Therapeutics in a research note on Thursday. Wall Street Zen lowered shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 21st. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $32.17.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $8.98 on Thursday. 4D Molecular Therapeutics has a 52 week low of $2.23 and a 52 week high of $12.34. The stock has a market capitalization of $513.03 million, a PE ratio of -3.71 and a beta of 2.99. The stock’s fifty day moving average is $8.73 and its 200-day moving average is $9.08.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its quarterly earnings results on Wednesday, March 18th. The company reported $0.43 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.96. The business had revenue of $85.09 million during the quarter, compared to analysts’ expectations of $30.86 million. 4D Molecular Therapeutics had a negative return on equity of 33.37% and a negative net margin of 164.43%. As a group, analysts forecast that 4D Molecular Therapeutics will post -2.84 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. AQR Capital Management LLC bought a new position in shares of 4D Molecular Therapeutics in the 1st quarter valued at about $46,000. Millennium Management LLC raised its stake in shares of 4D Molecular Therapeutics by 15.0% during the first quarter. Millennium Management LLC now owns 1,633,987 shares of the company’s stock worth $5,278,000 after buying an additional 213,264 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of 4D Molecular Therapeutics during the first quarter worth approximately $39,000. American Century Companies Inc. lifted its holdings in 4D Molecular Therapeutics by 11.5% in the second quarter. American Century Companies Inc. now owns 48,810 shares of the company’s stock valued at $181,000 after buying an additional 5,026 shares during the period. Finally, XTX Topco Ltd acquired a new position in 4D Molecular Therapeutics in the second quarter valued at approximately $292,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

Key 4D Molecular Therapeutics News

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue materially beat expectations — reported EPS $0.43 vs. consensus ~($0.53) and revenue $85.09M vs. $30.86M expected, signaling stronger commercial performance than feared. Zacks: Q4 Results
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and assigned an “outperform” rating, providing a high upside thesis that can attract momentum buyers. Benzinga: RBC PT Raise
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating and set a $26 price target, reinforcing analyst support for the shares. Benzinga: Chardan Reaffirmation
• Positive Sentiment: Company press release outlining full‑year 2025 financial results, operational highlights and expected upcoming milestones provides an updated roadmap that may support continued upside if clinical/commercial milestones are achieved. GlobeNewswire: FY2025 Results & Milestones
• Neutral Sentiment: Short‑interest notices in mid‑March show anomalous/zero reported short shares (entries list 0 shares and NaN changes), which is ambiguous and unlikely to be driving meaningful short‑squeeze dynamics at this time.
• Negative Sentiment: Despite the beat, underlying metrics remain mixed: 4DMT reported a very large negative net margin and negative return on equity, and some analysts still expect negative full‑year EPS. These fundamentals keep valuation and profitability risks on the table. Press Release / Financials

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.